Journal of Clinical Oncology, Vol 16, 1179-1187, Copyright © 1998 by American Society of Clinical Oncology

ARTICLES

Efficacy of quinolone prophylaxis in neutropenic cancer patients: a meta-analysis

EA Engels, J Lau and M Barza
Tupper Research Institute, Department of Medicine, New England Medical Center, Boston, MA 02111, USA. eric.engels@es.nemc.org

PURPOSE: To perform a meta-analysis to estimate the efficacy of quinolone antibiotics in preventing infections, fevers, and deaths among cancer patients neutropenic following chemotherapy. METHODS: We searched MEDLINE to identify randomized trials of quinolone prophylaxis, controlled either with no prophylaxis or trimethoprim/sulfamethoxazole (TMS) prophylaxis. We pooled relative risks for outcomes using a random-effects model. RESULTS: Eighteen trials with 1,408 subjects were included. Compared with no prophylaxis, quinolones significantly reduced the incidence of gram-negative bacterial infections (relative risk, 0.21; 95% confidence interval [CI], 0.12 to 0.37), microbiologically documented infections (0.65; 0.50 to 0.85), total infections (0.54; 0.31 to 0.95), and fevers (0.85; 0.73 to 0.99). Quinolone prophylaxis did not alter the incidence of gram-positive bacterial, fungal, or clinically documented infections, or infection-related deaths. Results were similar for trials that used TMS as the control regimen. Among those who received quinolones, the incidence of infections due to quinolone-resistant organisms was 3.0% (95% CI, 1.7% to 5.2%) for gram-negative species and 9.4% (95% CI, 5.3% to 16.3%) for gram-positive species. Based on limited data, the incidence of quinolone-resistant infections was not higher among quinolone recipients than controls. With fever as outcome, blinded trials found quinolones less efficacious than did unblinded trials. CONCLUSION: Quinolone prophylaxis substantially reduces the incidence of various infection-related outcomes, but not deaths, in these patients. Although this reduction in infections may translate into a decrease in morbidity, the reduction in fevers (and by extension, use of empiric antibiotics) appears small, and blinded trials provided less evidence for benefit than unblinded trials. Quinolone-resistant infections are uncommon, but continued vigilance is warranted.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				C. Cattaneo, G. Quaresmini, S. Casari, M. A. Capucci, M. Micheletti, E. Borlenghi, L. Signorini, A. Re, G. Carosi, and G. Rossi Recent changes in bacterial epidemiology and the emergence of fluoroquinolone-resistant Escherichia coli among patients with haematological malignancies: results of a prospective study on 823 patients at a single institution J. Antimicrob. Chemother., March 1, 2008; 61(3): 721 - 728. [Abstract] [Full Text] [PDF]

				F. Fernandez-Aviles, E. Carreras, A. Urbano-Ispizua, M. Rovira, C. Martinez, A. Gaya, M. Granell, L. Ramiro, C. Gallego, A. Hernando, et al. Case-Control Comparison of At-Home to Total Hospital Care for Autologous Stem-Cell Transplantation for Hematologic Malignancies J. Clin. Oncol., October 20, 2006; 24(30): 4855 - 4861. [Abstract] [Full Text] [PDF]

				A. G. Freifeld, K. A. Sepkowitz, N. G. Almyroudis, B. H. Segal, L. Castagna, A. Santoro, A. C. Pasqualotto, D. D. Rosa, A. L. Machado, J. I. Ito, et al. Antibacterial prophylaxis in patients with cancer and neutropenia. N. Engl. J. Med., January 5, 2006; 354(1): 90 - 94. [Full Text] [PDF]

				G. Bucaneve, A. Micozzi, F. Menichetti, P. Martino, M. S. Dionisi, G. Martinelli, B. Allione, D. D'Antonio, M. Buelli, A. M. Nosari, et al. Levofloxacin to Prevent Bacterial Infection in Patients with Cancer and Neutropenia N. Engl. J. Med., September 8, 2005; 353(10): 977 - 987. [Abstract] [Full Text] [PDF]

				M. Cullen, N. Steven, L. Billingham, C. Gaunt, M. Hastings, P. Simmonds, N. Stuart, D. Rea, M. Bower, I. Fernando, et al. Antibacterial Prophylaxis after Chemotherapy for Solid Tumors and Lymphomas N. Engl. J. Med., September 8, 2005; 353(10): 988 - 998. [Abstract] [Full Text] [PDF]

				W. H. Kruger, J. Bohlius, O. A. Cornely, H. Einsele, H. Hebart, G. Massenkeil, S. Schuttrumpf, G. Silling, A. J. Ullmann, D. T. Waldschmidt, et al. Antimicrobial prophylaxis in allogeneic bone marrow transplantation. Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Haematology and Oncology Ann. Onc., August 1, 2005; 16(8): 1381 - 1390. [Abstract] [Full Text] [PDF]

				A. Gafter-Gvili, A. Fraser, M. Paul, and L. Leibovici Meta-Analysis: Antibiotic Prophylaxis Reduces Mortality in Neutropenic Patients Ann Intern Med, June 21, 2005; 142(12_Part_1): 979 - 995. [Abstract] [Full Text] [PDF]

				F. H. van Tiel, M. M. Harbers, A. G. Kessels, and H. C. Schouten Home care versus hospital care of patients with hematological malignancies and chemotherapy-induced cytopenia Ann. Onc., February 1, 2005; 16(2): 195 - 205. [Abstract] [Full Text] [PDF]

				J. K. Waselenko, T. J. MacVittie, W. F. Blakely, N. Pesik, A. L. Wiley, W. E. Dickerson, H. Tsu, D. L. Confer, C. N. Coleman, T. Seed, et al. Medical Management of the Acute Radiation Syndrome: Recommendations of the Strategic National Stockpile Radiation Working Group Ann Intern Med, June 15, 2004; 140(12): 1037 - 1051. [Abstract] [Full Text] [PDF]

				M. Cruciani, M. Malena, O. Bosco, S. Nardi, G. Serpelloni, and C. Mengoli Reappraisal With Meta-Analysis of the Addition of Gram-Positive Prophylaxis to Fluoroquinolone in Neutropenic Patients J. Clin. Oncol., November 15, 2003; 21(22): 4127 - 4137. [Abstract] [Full Text] [PDF]

				L. Leibovici, K. Soares-Weiser, M. Paul, E. Goldberg, A. Herxheimer, and P. Garner Considering resistance in systematic reviews of antibiotic treatment J. Antimicrob. Chemother., October 1, 2003; 52(4): 564 - 571. [Abstract] [Full Text] [PDF]

				N. Dainiak, J. K. Waselenko, J. O. Armitage, T. J. MacVittie, and A. M. Farese The Hematologist and Radiation Casualties Hematology, January 1, 2003; 2003(1): 473 - 496. [Abstract] [Full Text] [PDF]

				C. Gomez-Martin, C. Sola, J. Hornedo, S. Perea, C. Lumbreras, V. Valenti, A. Arcediano, M. Rodriguez, R. Salazar, H. Cortes-Funes, et al. Rifampin Does Not Improve the Efficacy of Quinolone Antibacterial Prophylaxis in Neutropenic Cancer Patients: Results of a Randomized Clinical Trial J. Clin. Oncol., May 10, 2000; 18(10): 2126 - 2134. [Abstract] [Full Text] [PDF]